Estimated reading time: 2-3 minutes

DUBLIN — Taking Novo Nordisk’s new obesity drug can help reduce your risk of heart disease and help you lose weight, according to a new study from the United States.

A year after semaglutide was marketed as Wegovi, the risk of patients suffering a heart attack or stroke over the next ten years dropped from 7.6 percent to 6.3 percent, according to Mayo Clinic researchers. found.

The results, presented this week at the European Obesity Congress in Dublin, are among the first signs that weight loss from new GLP-1 agonist drugs like Wegovi may have heart health benefits — something scientists had hoped for, but it didn’t. You still have a lot of general information to verify.

The study was conducted among only 93 patients, and the researchers said that further and larger studies are needed to confirm that the effect of the reduction in risk is actually less morbidity and long-term mortality.

Novo is expected to announce the results after five years Select the test Looking at the health impact of injectable drugs, particularly around heart disease, later this year. Investors, governments and insurers are eagerly watching the data.

Dr. Andres Acosta, one of the researchers, told Reuters, “It is very important, because obesity is a risk factor for cardiovascular diseases.”

“So the question is, can we say that with 15% (average weight loss) of drugs, we’re improving cardiovascular risk and people are dying?” he said.

Risk is calculated using the American College of Cardiology’s calculator, based on data including blood pressure and cholesterol levels. The team assessed the risk before the patients – mainly white women, average BMI 39.8, but no history of heart disease – a year after taking the drug.

The study was reviewed by the organizers of the congress, the European Association for the Study of Obesity, but the full paper is not yet available. The study was not funded by Novo.

Recent health stories

More stories you might want

Leave a Reply

Your email address will not be published. Required fields are marked *